Eli Lilly in Talks to Acquire Ventyx Biosciences in USD 1 Billion-Plus Deal
A potential buyout of Ventyx will add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's pipeline, along with treatments for conditions like Parkinson's.
Written By : sheeba farhat
Published On 2026-01-07 10:22 GMT | Update On 2026-01-07 10:22 GMT
Advertisement
Bengaluru: Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than USD 1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Shares of Ventyx surged more than 50% in extended trading following the report, which said the deal could be announced imminently.
Also Read: Novo Nordisk Bets on Oral Wegovy to Take on Eli Lilly in US Obesity Market
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.